Friday, January 25, 2013 Thursday, January 24, 2013- Can Biologics Make You Rich?at Motley Fool (Thu, Jan 24)
- Ariad Pharmaceuticals Deemed a Recommended Buy and 4 Stock Analyses to Know Nowat Wall St. Cheat Sheet (Thu, Jan 24)
- Amgen Earnings: Beyond the Numbersat Motley Fool (Thu, Jan 24)
- New England Journal Of Medicine Articles Affirm Comparability Of Affymax's Omontys To Epogenat Seeking Alpha (Thu, Jan 24)
- Investor: San Francisco Now a ‘Target-rich’ Environment for Biotech M&Asat Motley Fool (Thu, Jan 24)
- Impax: FDA's Complete Response Letter For Rytary Presents Multiple Buying Opportunitiesat Seeking Alpha (Thu, Jan 24)
- Amgen Earnings Call Nuggets: the Bundle Rate and Dividends vs. Buybacksat Wall St. Cheat Sheet (Thu, Jan 24)
- Analysts' Actions: AAPL NFLX TIF BHI AMGNTheStreet (Thu, Jan 24)
- Snapshot: Brodkorb critically injured in car crash + Twin Cities driver dies after hitting 6 minivans + Tiger Woods left Calif. due to taxes + Delmon can make $600k if he makes weight + Who is winning smartphone race? — VIDEOat bizjournals.com (Thu, Jan 24)
- Amgen Misses on EPS, Guides AboveZacks (Thu, Jan 24)
- Early Movers: MMM, XRX, LUV & Moreat CNBC (Thu, Jan 24)
Wednesday, January 23, 2013Add AMGN News to My Yahoo!  | |
|